Subjective cognitive decline and risk of MCI

Harten, Argonde C. van; Mielke, Michelle M.; Swenson-Dravis, Dana; Hagen, Clinton E.; Edwards, Kelly K.; Roberts, Rosebud O.; Geda, Yonas E.; Knopman, David S.; Petersen, Ronald C.

doi:10.1212/wnl.0000000000005863

Cited by 209 publications

(206 citation statements)

References 44 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…Finally, the reported link between an individual's own cognitive concerns (rather than those of an informant) and AD biomarkers in asymptomatic individuals suggests that there may be additive utility in examining trajectories of cognitive complaints alongside cognitive decline to predict risk for clinical progression . This may also be extended to measures of mild neurobehavioral changes as well as potentially novel measures of health outcomes developed in coordination with patient and caregivers to better identify what is of value from an individual's perspective (e.g., driving, perceived competence, etc).…”

Section: Discussionmentioning

confidence: 99%

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Papp

Buckley

Mormino

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

Introduction Demonstrating the “clinical meaningfulness” of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid‐β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression. Methods Cox regression analyses were used to determine whether 3‐year slopes on the preclinical Alzheimer's cognitive composite predicted MCI diagnosis and global Clinical Dementia Rating>0 in 267 Aβ+ CN individuals participating in the Harvard Aging Brain Study, Australian Imaging, Biomarker and Lifestyle Study, and Alzheimer's Disease Neuroimaging Initiative. Results Steeper preclinical Alzheimer's cognitive composite decline over 3 years was associated with increased risk for MCI diagnosis and global Clinical Dementia Rating>0 in the following years across all cohorts. Hazard ratios using meta‐analytic estimates were 5.47 (95% CI: 3.25–9.18) for MCI diagnosis and 4.49 (95% CI: 2.84–7.09) for Clinical Dementia Rating>0 in those with subtle decline (>−.14 to −.26 preclinical Alzheimer's cognitive composite standard deviations/year) on longitudinal cognitive testing. Discussion Early “subtle cognitive decline” among Aβ+ CN on a sensitive cognitive composite demonstrably increases risk for imminent clinical disease progression and functional impairment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Papp

Buckley

Mormino

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…This perception needs to be taken seriously, especially since a clear definition of cognitive impairment is still lacking and the ecological validity of cognitive functioning assessments has been questioned . Recent data from an ageing, non‐MS population also suggest that patients may experience cognitive struggles before they can be measured objectively .…”

Section: Discussionmentioning

confidence: 99%

Perceived neuropsychological impairment inversely related to self‐reported health and employment in multiple sclerosis

D'hooghe

Cock

Benedict

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Multiple sclerosis (MS) patients frequently report cognitive difficulties which impact daily functioning. The objective was to investigate the relationship between patient‐reported cognitive impairment and depression, demographic and MS‐related variables, and to clarify its impact on self‐reported health measures and employment. Method A large two‐centre survey included the MS Neuropsychological Screening Questionnaire (MSNQ), the two‐question screening tool for depression, vitality, health‐related quality of life, the Health‐Promoting Lifestyle Profile II and questions assessing social network satisfaction and employment status. Results Of the 751 respondents (median age 54 years, median Expanded Disability Status Scale 5, 66.2% female), two‐thirds reported perceived neuropsychological impairment or depressive symptoms. Whilst depressive symptoms were related to higher MSNQ scores, the MSNQ poorly predicted depression. After correcting for confounders, higher MSNQ scores and depressive symptoms decreased vitality, health‐related quality of life and health‐promoting behaviours and increased the probability of being socially dissatisfied. In participants below retirement age, higher MSNQ and Expanded Disability Status Scale scores increased the probability of unemployment, whilst depression did not. Conclusion The contribution of the MSNQ to self‐reported health measures and its unique explanatory power regarding unemployment suggest that subjective cognitive complaints are connected to subtle, yet meaningful, neuropsychological dysfunction.

show abstract

“…MCI status was ascertained according to the ADNI and AIBL study criteria, which were consistent with accepted clinical methods [23,24] (Supplementary Material). SCD was classified as present in the ADNI data set among participants who did not qualify as having MCI if either the patient or informant Everyday Cognition Questionnaire score reached its respective threshold score (≥1.31 informants or ≥1.36 participants) [25–27]. For AIBL, SCD was classified as present by an IQcode 16‐item short form score of ≥3.38 [28,29].…”

Section: Methodsmentioning

confidence: 99%

“…MCI was defined using consensus agreement and published criteria [24,30]. SCD was determined to be present if the patient or informant Everyday Cognition Questionnaire score reached its respective threshold (≥1.31 informants or ≥ 1.36 participants) [25–27]. Aβ positivity was defined by Pittsburgh compound B PET standardized uptake value ratio >1.42 [31].…”

Section: Methodsmentioning

confidence: 99%

Practical algorithms for amyloid β probability in subjective or mild cognitive impairment

Maserejian

Bian

Wang

et al. 2019

Alz & Dem Diag Ass & Dis Mo

Self Cite

View full text Add to dashboard Cite

Introduction Practical algorithms predicting the probability of amyloid pathology among patients with subjective cognitive decline or mild cognitive impairment may help clinical decisions regarding confirmatory biomarker testing for Alzheimer's disease. Methods Algorithm feature selection was conducted with Alzheimer's Disease Neuroimaging Initiative and Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing data. Probability algorithms were developed in Alzheimer's Disease Neuroimaging Initiative using nested cross‐validation accompanied by stratified subsampling to obtain 1000 internally validated decision trees. Semi‐independent validation was conducted using Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Independent external validation was conducted in the population‐based Mayo Clinic Study of Aging. Results Two algorithms were developed using age and normalized immediate recall z‐scores, with or without apolipoprotein E ε4 carrier status. Both algorithms had robust performance across data sets and when substituting different recall memory tests. Discussion The statistical framework resulted in robust probability estimation. Application of these algorithms may assist in clinical decision‐making for further testing to diagnose amyloid pathology.

show abstract

Subjective cognitive decline and risk of MCI

Abstract: Prognostic value of SCD for incident MCI improves when both consistency of SCD and associated worry are evaluated.

Cited by 209 publications

References 44 publications

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Perceived neuropsychological impairment inversely related to self‐reported health and employment in multiple sclerosis

Practical algorithms for amyloid β probability in subjective or mild cognitive impairment

Contact Info

Product

Resources

About